SAN DIEGO, April 29, 2016 /PRNewswire/ -- aTyr Pharma,
Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the
discovery and development of Physiocrine-based therapeutics to
address severe rare diseases, today announced the Company's
participation in two upcoming investor conferences. John Mendlein, Ph.D., aTyr's CEO, will provide
an overview of the Company during the following presentations:
- Deutsche Bank 41st Annual Health Care Conference:
Wednesday, May 4, 2016 at 12:50 p.m.
ET at the InterContinental Hotel in Boston, MA
- Bank of America Merrill Lynch 2016 Health Care
Conference: Wednesday, May 11,
2016 at 5:00 p.m. PT
(8:00pm ET) at the Encore at Wynn Las
Vegas in Las Vegas, NV
The presentations will be webcast live through the "Investors"
section of the aTyr Pharma website
at www.atyrpharma.com. An audio replay will be
available for at least 30 days following the initial presentation
webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients suffering from severe rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological modulators. The Company's lead
candidate, Resolaris™, is a potential first-in-class intravenous
protein therapeutic for the treatment of rare myopathies with an
immune component. Resolaris is currently in a Phase 1b/2 clinical
trial in adult patients with facioscapulohumeral muscular dystrophy
(FSHD); a Phase 1b/2 trial in adult patients with limb-girdle
muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a
Phase 1b/2 trial in patients with an early onset form of FSHD. To
protect this pipeline, aTyr built an intellectual property estate
comprising over 70 issued or allowed patents and over 240 pending
patent applications that are solely owned or exclusively licensed
by aTyr. aTyr's key programs are currently focused on severe,
rare diseases characterized by immune dysregulation for which there
are currently limited or no treatment options. For more
information, please visit http://www.atyrpharma.com.
Contacts:
Mark Johnson
Senior Director, Investor Relations
mjohnson@atyrpharma.com
858-875-1101
Jesse Baumgartner
Stern Investor Relations, Inc.
jesse@sternir.com
212-362-1200
Logo -
http://photos.prnewswire.com/prnh/20120809/MM55538LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atyr-pharma-to-present-at-upcoming-may-investor-conferences-300260080.html
SOURCE aTyr Pharma, Inc.